EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of the Efficacy and Safety of Ceftobiprole, Vancomycin, Daptomycin, and Linezolid in the Treatment of Bloodstream Infections and Skin and Skin Structure Infections: A Network Meta‐Analysis

Li Wang, Xinnan Zheng, Linghui Chen, Jiale Qi, Yin Tan, Xingrong Shen, Debin Wang, Jing Chai

Canadian Journal of Infectious Diseases and Medical Microbiology · 2026-01 · 2026 (1)

DOI: 10.1155/cjid/4489050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Infectious Diseases and Medical Microbiology, online erschienen am 23.03.2026. Verfasst von Li Wang und 7 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Newton Fund, UK Research and Innovation, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study conducted a network meta‐analysis to compare the efficacy and safety of ceftobiprole compared to vancomycin, daptomycin, and linezolid in the treatment of skin and skin structure infections, and compared to vancomycin and daptomycin in the treatment of bloodstream infections.

Methods

This study conducted a systematic search in the PubMed, Embase, Cochrane Library, and the China National Knowledge Infrastructure databases with a cutoff date of June 13, 2024. The quality of the included randomized controlled trials was evaluated using the Cochrane Risk of Bias Assessment Tool. Statistical analyses were performed using RevMan 5.3 and Stata 15.1.

Results

The results indicate that daptomycin is the most effective treatment for bloodstream infections (70.2%), whereas ceftobiprole demonstrates the highest microbiological success (81.7%). In terms of skin and skin structure infections, the effectiveness (intention‐to‐treat population: 92.0%; clinically evaluable population: 83.0%) and microbiological success rate (intention‐to‐treat population: 80.5%; clinically evaluable population: 90.2%) of linezolid are higher than those of other antibiotics. Linezolid exhibits a higher overall occurrence of adverse events and death events compared to other antibiotics, whereas ceftobiprole demonstrates a lower incidence of both adverse events and death events.

Conclusions

Ceftobiprole shows a comprehensive therapeutic balance in treating skin and skin structure infections. In terms of bloodstream infections, ceftobiprole demonstrates a notable superiority in microbiological success rate. Moreover, the safety profile of ceftobiprole underscores its potential relative therapeutic advantage.

Förderung

  • Newton Fund
  • UK Research and Innovation
  • National Natural Science Foundation of China

Zitieren

APA

Wang, L., Zheng, X., Chen, L., Qi, J., Tan, Y., Shen, X., Wang, D., & Chai, J. (2026). Comparison of the Efficacy and Safety of Ceftobiprole, Vancomycin, Daptomycin, and Linezolid in the Treatment of Bloodstream Infections and Skin and Skin Structure Infections: A Network Meta‐Analysis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2026(1). https://doi.org/10.1155/cjid/4489050

Vancouver

Wang L, Zheng X, Chen L, Qi J, Tan Y, Shen X, et al. Comparison of the Efficacy and Safety of Ceftobiprole, Vancomycin, Daptomycin, and Linezolid in the Treatment of Bloodstream Infections and Skin and Skin Structure Infections: A Network Meta‐Analysis. Canadian Journal of Infectious Diseases and Medical Microbiology. 2026;2026(1). doi:10.1155/cjid/4489050

BibTeX
@article{Wang2026,
  author = {Wang, Li and Zheng, Xinnan and Chen, Linghui and Qi, Jiale and Tan, Yin and Shen, Xingrong and Wang, Debin and Chai, Jing},
  title = {Comparison of the Efficacy and Safety of Ceftobiprole, Vancomycin, Daptomycin, and Linezolid in the Treatment of Bloodstream Infections and Skin and Skin Structure Infections: A Network Meta‐Analysis},
  journal = {Canadian Journal of Infectious Diseases and Medical Microbiology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cjid/4489050}
}
Kostenlos starten →